Dapagliflozin in Patients with Chronic Kidney Disease. Reply.

作者信息

Heerspink Hiddo J L, Langkilde Anna-Maria, Wheeler David C

机构信息

University of Groningen, Groningen, the Netherlands

AstraZeneca, Gothenburg, Sweden.

出版信息

N Engl J Med. 2021 Jan 28;384(4):389-390. doi: 10.1056/NEJMc2032809.

DOI:10.1056/NEJMc2032809

PMID:33503362

Abstract

摘要

相似文献

[1]

Dapagliflozin in Patients with Chronic Kidney Disease. Reply.

N Engl J Med. 2021-1-28

[2]

The Authors' Reply to "How to Demonstrate the Impact of Dapagliflozin on Improving Hyperuricemia in Patients with Chronic Kidney Disease".

Intern Med. 2024-8-1

[3]

Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease.

Circulation. 2021-2-2

[4]

In brief: Dapagliflozin (Farxiga) for chronic kidney disease.

Med Lett Drugs Ther. 2021-7-26

[5]

Dapagliflozin in Patients with Chronic Kidney Disease.

N Engl J Med. 2021-1-28

[6]

Dapagliflozin in Patients with Chronic Kidney Disease.

N Engl J Med. 2021-1-28

[7]

Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease.

Ann Intern Med. 2023-7

[8]

Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease.

Ann Intern Med. 2023-7

[9]

Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial.

Lancet Diabetes Endocrinol. 2021-1

[10]

Dapagliflozin, advanced chronic kidney disease, and mortality: new insights from the DAPA-CKD trial.

Eur Heart J. 2021-3-31

引用本文的文献

[1]

Effect of Pharmacogenetics on Renal Outcomes of Heart Failure Patients with Reduced Ejection Fraction (HFrEF) in Response to Dapagliflozin.

Pharmaceutics. 2025-7-24

[2]

Dapagliflozin and metabolic dysfunction-associated steatohepatitis.

BMJ. 2025-6-4

[3]

The effect of ertugliflozin in patients with nonalcoholic fatty liver disease associated with type 2 diabetes mellitus: A randomized controlled trial.

Medicine (Baltimore). 2024-11-8

[4]

Biomarkers of Arginine Methylation in Diabetic Nephropathy: Novel Insights from Bioinformatics Analysis.

Diabetes Metab Syndr Obes. 2024-9-13

[5]

Impact of Dapagliflozin Adjunctive Therapy on the Progression of Chronic Kidney Disease in Patients with Type 2 Diabetes and Chronic Kidney Disease Stages 2-5: A systematic review and meta-analysis.

Sultan Qaboos Univ Med J. 2024-8

[6]

Treatment of membranous nephropathy: Perspectives on current and future therapies.

Front Nephrol. 2023-1-27

[7]

The sodium glucose co-transporter 2 inhibitor dapagliflozin ameliorates the fluid-retaining effect of the endothelin A receptor antagonist zibotentan.

Nephrol Dial Transplant. 2023-9-29

[8]

What's New in the Molecular Mechanisms of Diabetic Kidney Disease: Recent Advances.

Int J Mol Sci. 2022-12-29

[9]

Developing a contemporary community clinic for patients with heart failure with preserved ejection fraction within the current National Health Service model.

Open Heart. 2022-11

[10]

Non-invasive molecular imaging of kidney diseases.

Nat Rev Nephrol. 2021-10

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

新学期，新优惠

Dapagliflozin in Patients with Chronic Kidney Disease. Reply.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

推荐工具

Suppr 超能文献

相似文献

引用本文的文献